Initiale data indikerer, at effekten af lamivudin hos patienter med HBeAg- negativ CHB er ens med effekten hos patienter med HBeAg- positiv CHB, 71% af patienterne har HBV DNA suppression under detektionsgrænsen for assayet, 67% ALAT - normalisering og 38% med forbedring i HAI efter et års behandling.
Experience in patients with HBeAg negative CHB: initial data indicate the efficacy of lamivudine in patients with HBeAg negative CHB is similar to patients with HBeAg positive CHB, with 71% of patients having HBV DNA suppressed below the detection limit of the assay, 67% ALT normalisation and 38% with improvement in HAI after one year of treatment.